Can a simple blood test predict infections in CLL and myeloma patients?

NCT ID NCT05844033

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is looking for a better way to predict infection risk in people with chronic lymphocytic leukemia (CLL) or multiple myeloma. Researchers will use advanced lab tests on blood samples from 150 participants to find a biomarker that could warn doctors ahead of time. The goal is to personalize care and reduce serious infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could lead to a simple blood test that helps doctors predict which patients are at higher risk for infections, allowing for earlier preventive care.

What could go wrong

This is an observational study, not a treatment trial. The biomarker may not prove accurate enough for routine use, and results may take years to confirm.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital Cancer Center

    Boston, Massachusetts, 02215, United States